Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 05:31:07 pm
83.8 CHF   -0.06%
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
07:34aDJNOVARTIS : Oncology CEO Bruno Strigini to Retire
07:01a NOVARTIS : announces Oncology head to retire
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
83(c) 83.55(c) 83.85(c) 83.85(c) 83.8 Last
3 510 744 4 715 094 5 297 302 5 056 249 18 886 440 Volume
-0.12% +0.66% +0.36% 0.00% -0.06% Change
More quotes
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 962 M
Net income 2017 7 505 M
Debt 2017 17 812 M
Yield 2017 3,35%
Sales 2018 50 835 M
EBIT 2018 12 919 M
Net income 2018 8 600 M
Debt 2018 15 389 M
Yield 2018 3,51%
P/E ratio 2017 24,62
P/E ratio 2018 21,45
EV / Sales2017 4,89x
EV / Sales2018 4,68x
Capitalization 223 B
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
01/24Earnings Release
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
01:35p NOVARTIS : ACC Urges for Protection of Privilege in Johns Hopkins Univ. V Alcon ..
01:35p NOVARTIS : NAD Recommends Alcon Laboratories Discontinue Certain Claims for 'Cle..
11:34a NOVARTIS : Result of Oncology Ventures Drug Response Prediction for TKI drug fro..
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
07:34aDJNOVARTIS : Oncology CEO Bruno Strigini to Retire
07:01a NOVARTIS : announces Oncology head to retire
12/14 NOVARTIS : initiates study evaluating impact of higher dosing of Cosentyx® in pa..
12/14 NOVARTIS : Study Findings from Novartis Broaden Understanding of Kidney Cancer (..
12/14 NOVARTIS : New Angioedema Data Have Been Reported by Investigators at Novartis (..
12/14 STUDY DATA FROM NOVARTIS UPDATE UNDE : A Continuous Manufacturing Enabled Sequen..
More news
Sector news : Pharmaceuticals - NEC
03:12pDJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
08:48aDJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
07:25aDJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
12:05a Wall Street falls as investors fret about tax bill passage
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS 
NOVARTIS AG - 2016
A trend reversal can be anticipated
BUY
More Strategies
News from SeekingAlpha
09:54a UPCOMING CONVERSATION WITH AN EXPERT : Highlights In CAR-T
03:35a YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
12/14 Did ASH Just Change The Juno Best In Class Thesis?
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 3,0%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.16%222 673
JOHNSON & JOHNSON24.03%380 546
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759
AMGEN21.32%126 976